Ionis Pharmaceuticals

Ionis Pharmaceuticals

Yahoo Finance • 13 days ago

Cathie Wood Makes $64 Million Bet on Two Stocks

This article first appeared on GuruFocus. Cathie Wood's Ark Invest made a fresh round of high-conviction bets last week, adding heavily to Meta Platforms (NASDAQ:META) and Rocket Lab (NASDAQ:RKLB) while cutting exposure to several technol... Full story

Yahoo Finance • 13 days ago

Cathie Wood's Ark Invest weekly recap: boosts Meta, Rocket Lab; cuts Tempus AI, CrowdStrike

Cathie Wood’s Ark Invest boosted its technology, biotechnology, and space exposure last week, led by purchases of more than 51K shares of Meta Platforms (META [https://seekingalpha.com/symbol/META]) worth $38.2M and roughly 360K shares of... Full story

Yahoo Finance • 15 days ago

Novartis (NVS) and Bristol Myers (BMY) Pause Autoimmune CAR-T Studies. Can Their Programs Recover?

On September 1, 2026, the Wall Street Journal first reported that Novartis AG (NYSE:NVS) paused eight clinical trials of its experimental CAR-T cell therapy rap-cel in autoimmune and neurological conditions, including lupus, rheumatoid art... Full story

Yahoo Finance • 18 days ago

Ionis Delivers Positive Late-Stage Results for Two Partnered Drugs

Ionis Pharmaceuticals IONS announced positive results from two partnered programs, both of which are in phase III development. IONS Secures Phase III Win in ALS The first study, called FUSION, evaluated ulefnersen for the treatment of pa... Full story

Yahoo Finance • 18 days ago

Ionis announces positive interim data from partner Roche’s Phase 3 IMAgINATION study in IgA nephropathy (IgAN)

– Sefaxersen demonstrated statistically significant and clinically meaningful reductions in proteinuria versus placebo at 37 weeks, showing best-in-class potential – – IgAN is a progressive kidney disease that is typically diagnosed in yo... Full story

Yahoo Finance • 20 days ago

Cathie Wood Makes a Big AI Bet and Cuts Bitcoin Exposure

This article first appeared on GuruFocus. Cathie Wood's Ark Invest made a notable shift inside its technology portfolio last week, adding heavily to CoreWeave while cutting several other AI and technology positions. Ark bought about 239,... Full story

Yahoo Finance • 20 days ago

NVS Gets Positive CHMP Opinion for Cosentyx for Another Indication

Novartis NVS announced that the Committee for Medicinal Products for Human Use ("CHMP") of the European Medicines Agency ("EMA") has issued a positive opinion recommending marketing authorization for an additional indication of its arthrit... Full story

Yahoo Finance • 23 days ago

Can AstraZeneca's Broad Pipeline Offset Recent Setbacks?

AstraZeneca's AZN stock has taken a beating recently, with the company facing several pipeline setbacks in the past few months. AZN's Recent Pipeline Setbacks In July, AstraZeneca announced the failure of a phase III study evaluating Wai... Full story

Yahoo Finance • 24 days ago

Novartis (NVS) and Ionis (IONS)’ Big Cholesterol Bet Comes Up Short in Late-Stage Trial

On September 5, 2026, Reuters reported that pelacarsen, an experimental drug from Novartis AG (NYSE:NVS) and partner Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) meant to lower a cholesterol-carrying particle called Lp(a), failed to reduce he... Full story

Yahoo Finance • 26 days ago

Oligonucleotide Therapeutics Market Outlook 2026-2035 - Featuring Profiles of Alnylam Pharmaceuticals, Ionis Pharmaceuticals, and Sarepta Therapeutics

Company Logo Oligonucleotide Therapeutics Expand Beyond Rare Diseases as RNA Innovation, Targeted Delivery and Patient-Friendly Dosing Accelerate Adoption Dublin, Sept. 15, 2026 (GLOBE NEWSWIRE) -- "Oligonucleotide Therapeutics Market Op... Full story

Yahoo Finance • 27 days ago

Novartis Just Shook Up a Multibillion-Dollar Drug Race. What It Means for Eli Lilly Stock.

Novartis (NYSE: NVS) just reported its third clinical failure in only seven days. One of the company's pipeline setbacks triggered a ripple impact throughout one of the most hotly anticipated drug races in the biopharmaceutical industry.... Full story

Yahoo Finance • 28 days ago

Notable healthcare headlines for the week: UnitedHealth, Amgen, and CooperCompanies in focus

Wall Street rallied on Friday after the latest consumer inflation report came in broadly in line with expectations, helping ease concerns over price pressures and supporting a rebound across risk assets. On Friday, the Dow Jones Industria... Full story

Yahoo Finance • last month

BofA Sees Limited Damage from Novartis (NVS)’ Pelacarsen Miss While Citi Looks Towards Ionis (IONS)

Novartis AG's (NYSE:NVS) pelacarsen failed an important test. Although the experimental medicine lowered lipoprotein(a), or Lp(a), it did not produce a statistically significant reduction in cardiovascular events in the Phase 3 Lp(a)HORIZO... Full story

Yahoo Finance • last month

Royalty Pharma (RPRX): Can Downside Protection Offset Pelacarsen’s Phase 3 Failure?

Royalty Pharma plc (NASDAQ:RPRX) disclosed that pelacarsen failed the Phase 3 Lp(a)HORIZON cardiovascular-outcomes trial conducted by Novartis AG (NYSE:NVS). The randomized, double-blind study enrolled 8,323 patients with elevated lipoprot... Full story

Yahoo Finance • last month

Novartis' Del-desiran Fails Late-Stage DM1 Study, Shares Fall

Novartis AG NVS announced that the late-stage HARBOR study evaluating del-desiran in people living with myotonic dystrophy type 1 (DM1) failed to meet the primary endpoint. Del-desiran is an investigational antibody oligonucleotide conjug... Full story

Yahoo Finance • last month

Theravance Bio (TBPH) Up 0.8% Since Last Earnings Report: Can It Continue?

It has been about a month since the last earnings report for Theravance Biopharma (TBPH). Shares have added about 0.8% in that time frame, outperforming the S&P 500. But investors have to be wondering, will the recent positive trend conti... Full story

Yahoo Finance • last month

How Novartis' Double-Stacked Failures Reverberated Through Biopharma

Novartis and Ionis' high-profile Lp(a) flop on Friday reverberated through biotech stocks on Tuesday, leading to a widespread drop. Continue Reading... Full story

Yahoo Finance • last month

How Novartis And Ionis' High-Profile Failure Reverberated Through Biopharma

Novartis and Ionis' high-profile Lp(a) flop on Friday reverberated through biotech stocks on Tuesday, leading to a widespread drop. Continue Reading... Full story

Yahoo Finance • last month

Novartis Late-Stage Cardiovascular Outcome Study Fails, Stock Down

Novartis NVS announced that the late-stage study on investigational candidate, pelacarsen, failed. Pelacarsen is an investigational antisense oligonucleotide (ASO) designed to potently inhibit lipoprotein (a), Lp(a), production at its sou... Full story

Yahoo Finance • last month

Amgen Shares Fall as Novartis' Pelacarsen Misses Phase III Study Goal

Shares of Amgen AMGN were down 5% in after-hours trading on Friday after Novartis NVS announced that the phase III Lp(a)HORIZON study evaluating the latter's investigational drug pelacarsen in patients with elevated lipoprotein (a) Lp(a) a... Full story